Ketorolac Mylan (Ketorolac Trometamol)

Ketorolac trometamol works by non‑selectively inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2. This inhibition reduces the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever. Lower prostaglandin levels lead to decreased peripheral sensitisation and a reduction in pain perception at the site of injury.

The specific dose of Ketorolac Mylan is determined by the prescribing clinician based on the patient’s clinical condition, weight, renal function, and overall risk profile. Dosing regimens are individualized and should follow the prescriber’s instructions, adhering to the recommended maximum duration of therapy to avoid toxicity.

Ketorolac Mylan is generally avoided during the third trimester of pregnancy because of the risk of fetal renal impairment and premature closure of the ductus arteriosus. Use in earlier trimesters should only be considered if the potential benefit justifies the risk. Limited data are available for breastfeeding, and caution is advised; consult a healthcare professional before use.

To order Ketorolac Mylan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if required) and assist with any necessary import documentation.

Ketorolac offers potent analgesia comparable to moderate‑dose opioids but without the risk of respiratory depression or dependence. Compared with other NSAIDs, it has a stronger analgesic effect but a higher risk of gastrointestinal and renal adverse events, especially with prolonged use. It is therefore reserved for short‑term, severe pain where rapid relief is needed.

Ketorolac Mylan should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. The product must not be frozen or shaken vigorously. If the temperature range is temporarily exceeded, discard the vial according to local regulations. Always keep the medication in its original packaging until use.

Ketorolac Mylan is supplied as a sterile injectable solution for intramuscular (IM) or intravenous (IV) administration. The route, injection site and rate of infusion are determined by the prescribing clinician. Proper aseptic technique and appropriate dilution, if required, should be followed according to the product’s prescribing information.

Serious risks include gastrointestinal bleeding or perforation, acute renal failure, and severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of bleeding, sudden loss of kidney function, or allergic manifestations, and the drug should be discontinued immediately if any of these events occur.

Ketorolac Mylan is contraindicated in patients with known hypersensitivity to ketorolac or other NSAIDs, active peptic ulcer disease, recent gastrointestinal bleeding, severe renal impairment, and in the third trimester of pregnancy. Caution is also advised for individuals with uncontrolled hypertension, coronary artery disease, or those receiving anticoagulants, unless the prescriber determines that benefits outweigh the risks.